Institution Directory

Clinical trials at Mayo Clinic

Sites in Jacksonville, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

706

Shown on this page

Current sort

Live official records

Conditions: Patients With Any Degree of Carotid Artery Stenosis and Vulnerable Features in the Carotid Artery Plaque
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: High-risk Non-muscle Invasive Bladder Cancer
Interventions: Pembrolizumab, BCG; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2034
U.S. locations: 44
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more

Conditions: COPD, Chronic Obstructive Pulmonary Disease
Interventions: Targeted Lung Denervation (TLD); Device
Lead sponsor: Nuvaira, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Birmingham, Alabama • Jacksonville, Florida • Detroit, Michigan + 7 more

Conditions: Breast Cancer
Interventions: Abemaciclib, Standard Adjuvant Endocrine Therapy; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 5,637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 162
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more

Conditions: Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Interventions: 225Ac-ABD147; Drug
Lead sponsor: Abdera Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Newport Beach, California • San Francisco, California • Santa Monica, California + 9 more

Conditions: KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
Interventions: KQB365, Cetuximab, KQB198; Drug
Lead sponsor: Kumquat Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 11
States / cities: Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more

Conditions: Stage I Breast Cancer
Interventions: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane); Other · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 50 Years to 70 Years
Enrollment: 1,670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2041
U.S. locations: 812
States / cities: Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more

Conditions: Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma
Interventions: Computed Tomography, Endoscopic Procedure, Involved-site Radiation Therapy (3 Fractions), Involved-site Radiation Therapy (12 Fractions), Positron Emission Tomography, Questionnaire Administration; Procedure · Radiation · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more

Conditions: Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
Interventions: RP1, intra-tumoral injection, oncolytic virus; Biological
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 24
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 20 more

Conditions: Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions: Isosulfan Blue, Axillary Lymph Node Dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 96
States / cities: Little Rock, Arkansas • La Jolla, California • Martinez, California + 75 more

Conditions: Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma, Advanced Carcinoid Tumor, Advanced Cervical Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastric Carcinoma, Advanced Glioblastoma, Advanced Head and Neck Carcinoma, Advanced HER2 Positive Breast Carcinoma, Advanced Lung Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Germ Cell Tumor, Advanced Malignant Solid Neoplasm, Advanced Neuroendocrine Carcinoma, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Small Cell Neuroendocrine Carcinoma, Advanced Prostate Carcinoma, Hematopoietic and Lymphoid System Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome, Advanced Basal Cell Carcinoma, Advanced Cholangiocarcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Liver Carcinoma, Advanced Lymphoma, Advanced Malignant Testicular Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Penile Carcinoma, Advanced Primary Malignant Central Nervous System Neoplasm, Advanced Renal Cell Carcinoma, Advanced Sarcoma, Advanced Skin Squamous Cell Carcinoma, Advanced Urethral Carcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Advanced Appendix Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Interventions: Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Jacksonville, Florida • Grand Forks, North Dakota

Conditions: Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
Interventions: CGT4859; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more

About this Mayo Clinic institution page

What this page lists: ClinicalTrials.gov records that list Mayo Clinic in Jacksonville, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mayo Clinic

Filter and sort this campus

Live official records

Prospective Carotid Artery Stenosis Trial

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

About this Mayo Clinic institution page